Phase 1 Platinum Resistant Ovarian Cancer Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
Endometrial CancerTesticular CancerPlatinum Resistant Ovarian Cancer
Context Therapeutics Inc.156 enrolled14 locationsNCT06515613
Recruiting
Phase 1
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Ovarian CancerOvarian CarcinomaPlatinum Resistant Ovarian Cancer+4 more
Dana-Farber Cancer Institute18 enrolled2 locationsNCT06321484
Recruiting
Phase 1
GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer
Platinum Resistant Ovarian Cancer
Roswell Park Cancer Institute18 enrolled1 locationNCT07489287
Recruiting
Phase 1
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Platinum Resistant Ovarian Cancer
Stemline Therapeutics, Inc.100 enrolled6 locationsNCT07226427
Recruiting
Phase 1Phase 2
IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Platinum Resistant Ovarian Cancer
InxMed (Shanghai) Co., Ltd.150 enrolled7 locationsNCT05551507
Recruiting
Phase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1
A Study of MOv18 IgE in Patients With Solid Tumours That Express Folate Receptor Alpha
Triple-Negative Breast CancerEndometrial CancerTriple Negative Breast Cancer(TNBC)+3 more
Epsilogen Ltd45 enrolled7 locationsNCT06547840
Recruiting
Phase 1
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
Ovarian CancerEndometrial CancerOvarian Cancer Metastatic+4 more
Whitehawk Therapeutics, Inc.226 enrolled12 locationsNCT07444814
Recruiting
Phase 1
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Endometrial CancerPlatinum Resistant Ovarian CancerPROC
Whitehawk Therapeutics, Inc.265 enrolled12 locationsNCT07470853
Recruiting
Phase 1
A Study of MGC026 in Participants With Advanced Solid Tumors
Breast CancerColorectal, CancerGastric Cancer+19 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 1
A Study to Evaluate the Safety and Efficacy of OPB-101 in Platinum-resistant Ovarian Cancer
Ovarian CancerPlatinum Resistant Ovarian CancerOvarian Cancer Recurrent
Outpace Bio, Inc.30 enrolled4 locationsNCT07030907
Recruiting
Phase 1Phase 2
Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.
Platinum Resistant Ovarian CancerPlatinum-Resistant Fallopian Tube CarcinomaPlatinum-Resistant Primary Peritoneal Carcinoma+6 more
TILT Biotherapeutics Ltd.29 enrolled3 locationsNCT05271318